- Published on
Medicine – Bleeding Disorders: Coagulation Screening Tests
Coagulation screening tests are used to investigate bleeding disorders, identify abnormalities of haemostasis and monitor selected anticoagulant therapies.
The four classical investigations are:
- Prothrombin time (PT).
- Activated partial thromboplastin time (aPTT).
- Thrombin time (TT).
- Bleeding time (BT).
PT, aPTT and TT assess different stages of plasma coagulation (secondary haemostasis), whereas bleeding time historically assessed platelet-related primary haemostasis.
1. Prothrombin Time (PT)
PT measures the extrinsic and common coagulation pathways.
A. Coagulation Factors Assessed
- Extrinsic pathway: Factor VII.
- Common pathway: Factors X, V, II (prothrombin) and I (fibrinogen).
PT is particularly sensitive to factor VII deficiency and is used to monitor warfarin therapy through the international normalised ratio (INR).
B. Causes of Prolonged PT
- Warfarin therapy: Reduces vitamin K-dependent factors II, VII, IX and X.
- Vitamin K deficiency: Reduces synthesis of functional vitamin K-dependent coagulation factors.
- Liver disease: Impairs coagulation factor synthesis.
- Disseminated intravascular coagulation (DIC): Causes consumption of coagulation factors.
- Factor VII deficiency.
- Severe common-pathway factor deficiencies.
2. Activated Partial Thromboplastin Time (aPTT)
aPTT measures the intrinsic and common coagulation pathways.
A. Coagulation Factors Assessed
- Intrinsic pathway: Factors XII, XI, IX and VIII.
- Common pathway: Factors X, V, II and I.
B. Causes of Prolonged aPTT
- Unfractionated heparin: Enhances antithrombin-mediated inhibition of thrombin and factor Xa.
- Haemophilia A: Factor VIII deficiency.
- Haemophilia B: Factor IX deficiency.
- DIC: Consumption of coagulation factors.
- Severe liver disease: Reduced synthesis of coagulation factors.
- Lupus anticoagulant: Interferes with phospholipid-dependent coagulation assays.
- Von Willebrand disease: May prolong aPTT when factor VIII activity is sufficiently reduced.
- Factor XI or XII deficiency.
- Specific coagulation factor inhibitors.
Warfarin may also cause a modest increase in aPTT, particularly when its anticoagulant effect is marked, although PT/INR is the preferred monitoring test.
Despite its name, lupus anticoagulant is commonly associated with thrombosis rather than bleeding. It prolongs phospholipid-dependent clotting tests in vitro but may promote thrombosis in vivo. Not every patient with antiphospholipid syndrome has a prolonged aPTT.
3. Thrombin Time (TT)
TT measures the conversion of fibrinogen into fibrin after thrombin is added to plasma.
It evaluates the final step of clot formation rather than the entire common coagulation pathway.
Causes of Prolonged TT
- Heparin therapy: Inhibits thrombin through antithrombin.
- DIC: May cause reduced fibrinogen and increased fibrin degradation products.
- Hypofibrinogenaemia: Reduced fibrinogen concentration.
- Dysfibrinogenaemia: Abnormal fibrinogen function.
- Direct thrombin inhibitors: Such as dabigatran.
- Severe liver disease with abnormal fibrinogen.
4. Bleeding Time (BT)
Bleeding time is a historical investigation of primary haemostasis, reflecting platelet number, platelet function and vascular factors.
It is no longer recommended as a routine diagnostic test because of poor reproducibility and limited diagnostic accuracy.
Causes of Prolonged Bleeding Time
- Thrombocytopenia: Reduced platelet count.
- Von Willebrand disease: Defective platelet adhesion.
- Aspirin: Irreversible inhibition of platelet cyclooxygenase-1.
- Other antiplatelet drugs.
- Inherited platelet function disorders, such as Glanzmann thrombasthenia.
- Acquired platelet dysfunction, including uraemia.
5. Coagulation Pathways – Visual Summary
PT assesses the extrinsic and common pathways, aPTT assesses the intrinsic and common pathways, and TT measures fibrinogen-to-fibrin conversion. Bleeding time assesses primary haemostasis and is not represented in this coagulation cascade.
6. Comparison of Coagulation Screening Tests
| Test | Main Function | Causes of Prolongation |
|---|---|---|
| PT | Extrinsic and common pathways | Warfarin, vitamin K deficiency, liver disease, DIC, factor VII deficiency |
| aPTT | Intrinsic and common pathways | Heparin, haemophilia A/B, lupus anticoagulant, DIC, liver disease |
| TT | Fibrinogen-to-fibrin conversion | Heparin, dabigatran, low or abnormal fibrinogen, DIC |
| BT | Historical assessment of primary haemostasis | Thrombocytopenia, VWD, aspirin, platelet dysfunction |
7. Typical Laboratory Patterns in Bleeding Disorders
| Disorder | PT | aPTT | Platelets |
|---|---|---|---|
| Warfarin therapy | ↑ | Normal / ↑ | Normal |
| Vitamin K deficiency | ↑ | Normal / ↑ | Normal |
| Unfractionated heparin | Usually normal | ↑ | Usually normal |
| Haemophilia A/B | Normal | ↑ / Normal in mild disease | Normal |
| Von Willebrand disease | Normal | Normal / ↑ | Usually normal |
| DIC | Often ↑ | Often ↑ | ↓ |
| Liver disease | Often ↑ | Normal / ↑ | Normal / ↓ |
| Immune thrombocytopenia (ITP) | Normal | Normal | ↓ |
| Lupus anticoagulant | Usually normal | May be ↑ | Usually normal |
↑ = prolonged or increased; ↓ = reduced. These are typical patterns rather than universal findings. Disease severity, medications and laboratory reagents may affect results.
8. Interpretation of Abnormal PT and aPTT
Normal PT and aPTT do not exclude clinically important bleeding disorders. Results should always be interpreted alongside the clinical history, platelet count, fibrinogen concentration and medication exposure.
9. Mixing Study
A mixing study is useful when PT or aPTT is unexpectedly prolonged.
The patient's plasma is mixed with normal plasma, and the clotting time is reassessed.
- Correction: Suggests a coagulation factor deficiency.
- Failure to correct: Suggests an inhibitor, such as lupus anticoagulant, or an anticoagulant drug effect.
- Time-dependent inhibition: May suggest an acquired factor VIII inhibitor.
Interpretation depends on the assay, degree of correction and incubation conditions.
Mixing Study Flowchart
10. High-Yield Examination Summary
| Test | Key Examination Point |
|---|---|
| PT | Extrinsic and common pathways; prolonged with warfarin, vitamin K deficiency, liver disease and DIC |
| aPTT | Intrinsic and common pathways; prolonged with heparin, haemophilia, DIC and lupus anticoagulant |
| TT | Fibrinogen-to-fibrin conversion; prolonged with heparin, direct thrombin inhibitors and fibrinogen abnormalities |
| BT | Historical platelet-related test; prolonged with thrombocytopenia, VWD and antiplatelet therapy |
| Mixing study | Correction suggests deficiency; failure to correct suggests inhibitor or anticoagulant effect |
11. Key Examination Pearls
- PT = extrinsic + common pathway.
- aPTT = intrinsic + common pathway.
- TT = conversion of fibrinogen to fibrin.
- BT = historical assessment of primary haemostasis.
- Warfarin predominantly prolongs PT/INR.
- Unfractionated heparin commonly prolongs aPTT and TT.
- Haemophilia A and B usually cause isolated aPTT prolongation.
- DIC often prolongs both PT and aPTT and reduces platelet count.
- Von Willebrand disease may have normal PT and aPTT.
- Lupus anticoagulant may prolong aPTT despite its association with thrombosis.
- Normal PT and aPTT do not exclude a clinically significant bleeding disorder.
An isolated prolonged PT suggests an extrinsic pathway abnormality; an isolated prolonged aPTT suggests an intrinsic pathway abnormality; and prolongation of both suggests a common-pathway or multiple-factor abnormality. Always interpret the findings alongside platelet count, fibrinogen, medication history and clinical bleeding pattern.
Coagulation screening tests do not measure overall bleeding risk reliably in every clinical situation. Patients with significant bleeding or suspected coagulation abnormalities require interpretation of laboratory results in the context of clinical findings and, when indicated, specialist haematology assessment.
Kembara Xtra – Medicine Revision Notes